May 4, 2020 / 11:41 AM / 25 days ago

BRIEF-Lupin Says Positive Topline Results From Phase 3 Study Of Single-Dose Solosec For Treatment Of Trichomoniasis

May 4 (Reuters) - Lupin Ltd:

* LUPIN LTD SAYS POSITIVE TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF SINGLE-DOSE SOLOSEC (SECNIDAZOLE) FOR TREATMENT OF TRICHOMONIASIS.

* LUPIN LTD SAYS PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED IN PHASE 3 CLINICAL TRIAL OF 147 PATIENTS

* LUPIN LTD SAYS SOLOSEC 2G ORAL GRANULES WAS GENERALLY WELL-TOLERATED AMONG STUDY SUBJECTS

* LUPIN LTD SAYS PLANS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION FOR SOLOSEC® TO THE U.S. FDA FOR THE TREATMENT OF TRICHOMONIASIS IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below